Home
HelpTest Code NCDCS Neurochondrin Antibody, Cell-Binding Assay, Serum
Specimen Required
Only orderable as a reflex. For more information see:
-DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum
-ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
-EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum
-MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum
-MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
-PCDES / Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Serum
Useful For
Evaluating neurochondrin-IgG by cell-binding assay using serum from patients presenting with cerebellar and brainstem syndrome
Testing Algorithm
If the indirect immunofluorescence (IFA) pattern suggests neurochondrin, then this test and neurochondrin antibody IFA titer will be performed at an additional charge.
Method Name
Only orderable as a reflex. For more information see:
-DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum
-ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
-EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum
-MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum
-MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
-PCDES / Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Serum
Cell-Binding Assay (CBA)
Reporting Name
Neurochondrin CBA, SSpecimen Type
SerumSpecimen Minimum Volume
See Specimen Required
Specimen Stability Information
| Specimen Type | Temperature | Time | Special Container |
|---|---|---|---|
| Serum | Refrigerated (preferred) | 28 days | |
| Frozen | 28 days | ||
| Ambient | 72 hours |
Reject Due To
| Gross hemolysis | Reject |
| Gross lipemia | Reject |
| Gross icterus | Reject |
Clinical Information
Neurochondrin is a neuronal target antigen in autoimmune cerebellar degeneration. Patients positive for neurochondrin-IgG present with a subacute to chronic cerebellar and brainstem syndrome. Patients respond to long-term immunosuppressive treatment with clinical stabilization or improvement.
Reference Values
Only orderable as a reflex. For more information see:
-DMS2 / Dementia, Autoimmune/Paraneoplastic Evaluation, Serum
-ENS2 / Encephalopathy, Autoimmune/Paraneoplastic Evaluation, Serum
-EPS2 / Epilepsy, Autoimmune/Paraneoplastic Evaluation, Serum
-MAS1 / Myelopathy, Autoimmune/Paraneoplastic Evaluation, Serum
-MDS2 / Movement Disorder, Autoimmune/Paraneoplastic Evaluation, Serum
-PCDES / Pediatric Autoimmune Encephalopathy/CNS Disorder Evaluation, Serum
Negative
Interpretation
A positive result supports a diagnosis of central nervous system autoimmunity. Typical neurological phenotypes encountered include cerebellar ataxia and brainstem encephalitis. A paraneoplastic basis should be considered (uterine cancer in women) though cancers are, generally, not detected. Neurological stabilization or improvement may occur with immune therapy.
Cautions
A negative result does not exclude neurological autoimmunity or cancer
Method Description
Patient specimen is applied to a composite slide containing transfected and nontransfected HEK-293 cells. After incubation and washing, fluorescein-conjugated goat-antihuman IgG is applied to detect the presence of patient IgG binding.(Package insert: IIFT: Neurology Mosaics, Instructions for the indirect immunofluorescence test. EUROIMMUN;Â FA_112d-1_A_UK_C13, 02/2019)
Day(s) Performed
Monday through Sunday
Report Available
5 to 10 daysPerforming Laboratory
Mayo Clinic Laboratories in Rochester
Test Classification
This test was developed and its performance characteristics determined by Mayo Clinic in a manner consistent with CLIA requirements. It has not been cleared or approved by the US Food and Drug Administration.CPT Code Information
86255
LOINC Code Information
| Test ID | Test Order Name | Order LOINC Value |
|---|---|---|
| NCDCS | Neurochondrin CBA, S | 101450-5 |
| Result ID | Test Result Name | Result LOINC Value |
|---|---|---|
| 615865 | Neurochondrin CBA, S | 101450-5 |